

Special Issue

High-Sensitivity Lateral Flow Assays for SARS-CoV-2 and Other Infections, 2nd Edition

Message from the Guest Editor

Point-of-care testing (POCT) is applicable to a variety of areas of medicine and can make a significant difference in patient care. Lateral flow assays (LFAs) are critical in POCT. An LFA is a simple-to-use piece of diagnostic equipment that is used to confirm the presence or absence of a target analyte, such as SARS-CoV-2 or other infective agents, biomarkers in humans or animals, or pollutants in drinking water, food, or animal feed; however, its clinical utility has been questioned due to its limited sensitivity. Numerous strategies are used to improve sensitivity and quantitative detection, e.g., employing several visualization methods, using different labeling reporters, and integrating LFAs into other detection methods, resulting in their benefiting from both LFAs and the advantages of integrated detection devices for SARS-CoV-2 or other infections. This Special Issue invites submissions of novel and innovative original studies as well as comprehensive reviews on this topic.

- lateral flow assay
- point-of-care testing
- SARS-CoV-2
- high sensitivity
- detection device
- labeling reporters
- antigens
- pathogens

Guest Editor

Dr. Hideya Kawasaki

Nanosuit Research Laboratory, Division of Preeminent Bioimaging Research, Institute of Photonics Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

Deadline for manuscript submissions

closed (30 June 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/171802

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).